Mandos Gains FDA Approval for Lembaz in Infantile-Onset Niemann-Pick Disease Type C
FDA approves Lembaz for infantile-onset NPC using external control survival data, setting a precedent for rare disease regulatory strategy.


External control data drawn from an expanded access program has anchored a full FDA approval, a regulatory construct that rare disease sponsors and their QA counterparts will need to examine closely. Mandos, LLC, a subsidiary of Beren Therapeutics, PBC, received FDA approval on November 17, 2026 for Lembaz (adrabetadex) injection, the first therapy to demonstrate a survival benefit in patients with infantile-onset Niemann-Pick disease type C (NPC).
The approval covers adult and pediatric patients weighing at least 7 kg whose neurological symptoms began before age 6. Lembaz is administered intrathecally every two weeks by a trained healthcare provider, a delivery route that carries its own GMP and handling implications for hospital pharmacies and compounding-adjacent operations managing intrathecal formulations.
The evidentiary basis is notable for regulatory affairs leads. The FDA evaluated survival data from 36 patients across three clinical studies and an expanded access program, matching treated patients against an external control cohort rather than a concurrent randomized arm. Treated patients showed a 55% reduction in risk of death, with median overall survival of 8.5 years versus 4.9 years in the matched control group. The survival benefit held regardless of concomitant miglustat use. This external-control methodology, applied to a survival endpoint under a Breakthrough Therapy designation, sets a precedent sponsors developing rare disease programs under accelerated pathways should document against their own evidence-generation strategies.
Two therapies were previously approved for NPC, but neither carried a survival claim, and both imposed age and weight restrictions that excluded the youngest patients. Lembaz addresses that gap directly, though its safety profile introduces a monitoring obligation that QA and pharmacovigilance teams must build into post-market surveillance frameworks. The product carries a boxed warning for hearing impairment, including permanent hearing loss. Baseline audiological assessment is required before treatment initiation, with periodic re-evaluation throughout the treatment course; dose adjustments are tied to those findings.
Additional adverse events include balance and coordination disturbances, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough, a profile consistent with intrathecal administration and the underlying neurological disease burden.
The post-market hearing surveillance requirement will serve as a measurable compliance checkpoint for sites managing Lembaz administration as the product moves into clinical practice.
Source: U.S. Food and Drug Administration via FDA.gov press announcements, November 17, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding

Innate Pharma Achieves Phase 1 Milestone for IPH4502 ADC with Linker Stability Signal

Discussion